{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-015324","form_type":"8-K","ticker":null,"cik":"0001792581","company_name":"Kiromic Biopharma, Inc.","filed_at":"2023-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.265725+00:00","generated_at":"2026-06-11T02:27:58.910526+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kiromic BioPharma issues $2.4M 25% senior secured convertible note due 2024","bullets":["Principal $2.4M, 25% annual interest, matures Aug 25, 2024.","Convertible into common stock at $5.00 per share, subject to 9.99% beneficial ownership cap.","Secured by all of the Company’s intellectual property and fixtures/equipment.","Issued in a private placement exempt from registration under Section 4(a)(2) of the Securities Act.","Company must obtain stockholder approval for conversion shares exceeding Nasdaq share cap (19.99% of outstanding)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-015324","json":"https://secwatch.observer/filing/0001558370-23-015324.json","markdown":"https://secwatch.observer/filing/0001558370-23-015324.md","text":"https://secwatch.observer/filing/0001558370-23-015324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023015324/0001558370-23-015324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023015324/krbp-20230825x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T02:27:58.910526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"db0edd31da92baba300defb33d55ba94af1c62a8","claim":"Kiromic Biopharma, Inc. incurred convertible notes of $2,400,000 with an accredited investor at 25% per annum maturing August 25, 2024.","evidence_excerpt":"On August 25, 2023, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,400,000, bears interest at a rate of 25% per annum (the “Stated Rate”) and matures on August 25, 2024 (the “Maturity Date”)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023015324/0001558370-23-015324-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$2,400,000"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Rate","value":"25% per annum"},{"label":"Maturity","value":"August 25, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"d1540535e97725b40cf81cfe91c1f67b9d230237","claim":"Kiromic Biopharma, Inc. entered into Note with an accredited investor valued at $2,400,000 (effective 2023-08-25).","evidence_excerpt":"On August 25, 2023, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,400,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023015324/0001558370-23-015324-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Value","value":"$2,400,000"},{"label":"Effective","value":"2023-08-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}